Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia

This is a randomized, placebo-controlled, double-blind, single site study that uses an fMRI
measurement to assess brain activation during attention and reading tasks and the effects of
atomoxetine in reducing symptoms of ADHD in participants with ADHD and comorbid dyslexia.
Similar assessments are performed in two additional groups of participants with ADHD only and
dyslexia only to determine to what extent symptomatic change in the comorbid ADHD & dyslexia
is achieved independently by atomoxetine effects on either condition. A healthy control group
of non-ADHD, non-dyslexia subjects (20) will be included to monitor practice effects &
effects of treatment that may be interpreted as normal maturation. The healthy control group
will not be treated with any study medications.

Inclusion Criteria:

- Participants in the ADHD-only or ADHD+dyslexia groups must meet DSM-IV-TR criteria for
ADHD

- Participants in the dyslexia-alone group or ADHD+dyslexia groups must meet criteria
for dyslexia

- Participants must achieve a score of 80 or more on the Full Scale Intelligence
Quotient

- Child or adolescent participants must be 10 to 16 years old

- Must be able to communicate in English

- Must be able to swallow capsules

- Be reliable to keep appointments for clinic visits & all related tests

- Participants for healthy control group do not meet DSM-IV-TR criteria for ADHD and/or
dyslexia

- Participants for healthy control group must achieve a score of at least 80 but not
>120 on the Full Scale Intelligence Quotient

Exclusion Criteria:

- Participants who weigh less than 25.1 kilogram (kg) or greater than 70 kg.

- Participants with severe allergies to more than 1 class of medications or who have had
multiple adverse drug reactions

- Participants with prior diagnosis of bipolar I or bipolar II disorder or psychosis

- Participants with documented history of autism, Asperger's syndrome, or pervasive
developmental disorder

- Females who are pregnant or breastfeeding

- Participants treated with atomoxetine at a therapeutic dose (1.2 mg/kg/day) for at
least 4 to 6 weeks